Liquid Biopsy for Lung Cancer

Overseen By Nathan Pennell, MD, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Case Comprehensive Cancer Center

Disqualifiers: Prior therapy, Prior molecular testing

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

26 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial aims to see if using blood tests can help start treatment sooner for patients with newly diagnosed lung cancer. The goal is to reduce the time it takes to begin treatment.

Research Team

Nathan A. Pennell

Principal Investigator

Cleveland Clinic, Case Comprehensive Cancer Center

Eligibility Criteria

This trial is for new patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who plan to receive systemic therapy and are referred to the Cleveland Clinic Taussig Cancer Center without prior genetic testing results. It's not open to those who've had previous treatment or adequate molecular testing for their current NSCLC diagnosis.

Inclusion Criteria

I plan to get my treatment at Cleveland Clinic or another site but will follow up or share my records with Cleveland Clinic.

I have advanced non-squamous NSCLC and was referred to the Cleveland Clinic without prior genetic testing results.

Exclusion Criteria

I have received treatment for non-small cell lung cancer before.

You have already had the necessary genetic testing for your lung cancer diagnosis.

Treatment Details

Interventions

• Liquid biopsy

Trial Overview The study is examining whether liquid biopsies can speed up the start of treatment in advanced NSCLC patients. A liquid biopsy involves taking a blood sample to search for cancer cells, which may help in quicker decision-making regarding therapy.

Participant Groups

Group I: Liquid biopsy Experimental Treatment 1 Intervention

A liquid biopsy is a test will be done on a sample of blood to look for cancer cells

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials

472

Recruited

33,400+